ARIC Manuscript Proposal #2055

1.a.   Full Title: Assessing cardiovascular risk in diabetics using traditional indicators of target organ damage and serum biomarkers: the ARIC study

  b. Abbreviated Title (Length 26 characters): **target organ damage and cardiovascular events.**

2.   Writing Group:
        Writing group members: Mauro Gori, Deepak Gupta, Natalie Bello, Brian Claggett, Amil Shah, Hicham Skali; Aaron Folsom; Christie M Ballantyne; Brad C Astor; Barbara Klein, Kunihiro Matsushita; David Aguilar, Orly Vardeny; Hanyu Ni; Elizabeth Selvin, Scott D. Solomon….. <mark>OTHERS WELCOME</mark>

I, the first author, confirm that all the coauthors have given their approval for this manuscript proposal. _MG_ **[please confirm with your initials electronically or in writing]**

    First author: **Mauro Gori**
       Address: 75 Francis Street
                     Boston, MA 02115

          Phone: 617-525-6738   Fax: 617-582-6027
          E-mail: mgori@partners.org

ARIC author to be contacted if there are questions about the manuscript and the first author   does not respond or cannot be located (this must be an ARIC investigator).
    Name: Scott D Solomon, MD
    Address: 75 Francis Street
              Boston, MA 02115

          Phone: 857-307-1960 Fax: 857-307-1944
          E-mail: ssolomon@rics.bwh.harvard.edu

   3.   Timeline:
Analysis will begin once this manuscript proposal is approved. Anticipate manuscript completion in approximately the following 12 months.

   4.   Rationale:

Cardiovascular disease (CVD) is the most common cause of death among persons with diabetes, and the presence of multiple organ damage further impacts on the prognosis of these individuals.[1,2,3,4,5,6,7,8,9,10]

Among persons with diabetes, there is heterogeneity in the risk of CVD such that accurate risk assessment depends on a variety of individual patient characteristics, like number of concomitant risk factors, duration of diabetes, presence of coronary heart disease (CHD), overall atherosclerotic burden, presence of proteinuria.[11,12,13,14] Consequently, measuring target organ damage may be an attractive approach to improving risk prediction of cardiovascular outcome in diabetics. As the great vessels, kidneys, eyes, and heart are commonly affected by diabetes, several markers of diabetic involvement of these organ systems already exist. The ankle brachial index (ABI) can be used as a measure of atherosclerosis in peripheral vessels, while another validated index of generalized atherosclerosis is the B-mode ultrasound detected carotid intima media thickness (CIMT). Nephropathy can be assessed by estimated glomerular filtration rate and urine albumin/creatinine ratio (UACR), while retinopathy can be detected by retinal photography. The ECG can demonstrate abnormalities as manifestations of diabetic induced cardiac damage. All of these measures of target organ damage are commonly used in population-based studies because they are relatively inexpensive, noninvasive, and easy to assess. Importantly, each one of these measures of target organ damage has been strongly associated with cardiovascular events.[15,16,17,18,19,20,21,22,23,24,25,26,27,28,29] Other potentially useful measures of target organ damage in diabetics include serum biomarkers such as NTproBNP, hsTnT, hsCRP. NTproBNP and hsTnT have been used to improve the accuracy in the diagnosis of subclinical left ventricular dysfunction, while hsCRP have been related to inflammation and atherogenesis. Importantly, these serum biomarkers have also been found to be markers of adverse CV outcome both in the general population and in persons with diabetes. [30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47]

Among subjects with diabetes few population-based studies have compared the differential predictive value of several measures of target organ damage,[48,49,50] let along taking into account the serum biomarkers.[51] The ARIC Study, a population-based cohort study of middle age men and women, is the ideal setting to select diabetic persons without prevalent CVD and prospectively investigate several noninvasive measures of target organ damage and combinations of these measures in relation to incident CVD outcome. *Specifically, we propose to evaluate the association of established tests of target organ damage (ABI, CIMT, retinopathy, nephropathy, ECG) and of serum biomarkers (NTproBNP, hsTnT, hsCRP) on the primary outcome of fatal or nonfatal CV events in persons with diabetes. Additionally, we will evaluate whether the association between established markers of target organ damage and CV risk is modified by serum biomarkers.*

5. Main Hypothesis/Study Questions:
Among diabetic ARIC participants without prevalent CVD at visit 4 the aims of the study are:
1) To describe the prevalence, clinical characteristics, and correlations of specific measures of target organ damage.
2) To describe the event rates for the primary outcome (see definition of outcome variables) according to types of target organ damage.

3) To compare the differential risk of the primary outcome associated with specific measures of target organ damage (traditional markers and serum biomarkers). We will test for independent associations of specific markers of target organ damage with the risk of the primary and secondary outcomes (see definition of outcome variables) in univariate and multivariate adjusted models (adjusting for baseline age, sex, race, center, smoking status, pack of cigarettes/year, body mass index, waist-hip ratio, systolic blood pressure, hypertensive medication use, diabetic medication use, lipid lowering medication, aspirin use, education, total/HDL cholesterol, triglycerides, family history of CHD).

4) To describe effect modification on the primary outcome by serum biomarkers on traditional measures of target organ damage.

6. Design and analysis (study design, inclusion/exclusion, outcome and other variables of interest with specific reference to the time of their collection, summary of data analysis, and any anticipated methodological limitations or challenges if present).

Study design/population:

Cohort analysis of diabetic participants without history of cardiovascular disease at visit 4. The study population will be comprised of persons with diabetes with available data regarding ECG, ABI, CIMT, eGFR, UACR, hsTnT, NTproBNP, hsCRP at visit 4, as well as retinal photography, CIMT, ABI from visit 3, or ABI from visit 1. We anticipate an estimate of 1500 persons with diabetes with these characteristics.

Definition of Diabetes

Participants will be classified as having a history of diabetes at visit 4 if they report a physician diagnosis of diabetes or medications for diabetes at visit 4 or previous visits. Undiagnosed diabetes will be defined as a fasting glucose $\geq$126 mg/dl or non-fasting glucose $\geq$200 mg/d at visit 4 or previous visits.

Exclusions:

We will exclude ethnicity other than black or white, missing data on target organ damage tests, or missing covariates of interest. Participants with prevalent CVD at visit 4 will be excluded.

Definition of Prevalent CVD

CHD: defined as self-reported myocardial infarction (MI) before visit 1, or silent MI (diagnosed by ECG Q waves), validated MI event, or revascularization procedure between visit 1 and 4.

HF: defined as either participants reported medication use for heart failure or Gothenberg score=3 [52,53] or missing HF status, or incident HF hospitalization (based upon ICD-9 codes 428.xx) prior to visit 4.

Stroke: defined as self-reported stroke before visit 1 or incident stroke between visit 1 and visit 4.

Exposure variables:

Traditional indicators of target organ damage

1) Retinopathy (visit 3)

Retinopathy will be defined as present if any characteristic lesion as defined by the Early Treatment Diabetic Retinopathy Study severity scale was present (microaneurysms, hemorrhages, cotton wool spots, intraretinal microvascular abnormalities, hard exudates, and new retinal vessels).[54]

2) Major ECG abnormalities (visit 4)

ECG abnormalities will be defined as present if any major criteria are met.

Major electrocardiographic abnormalities will be defined according to the Minnesota coding system [50,55,56] as:

Ventricular conduction defect codes:

7-1 (left bundle branch block),

7-2 (right bundle branch block),

7-4 (IV block of indeterminate type with QRS >120 ms);

Left ventricular hypertrophy codes:

3-1, 3-3

4-1 to 4-3

5-l to 5-3

Isolated major ST-T wave abnormalities (ST-T) codes:

4-1, 4-2

5-1, 5-2 without (3-1, 3-3, l-l to l-3);

Atria1 fibrillation code:

8-3

3) Nephropathy (visit 4)

Nephropathy will be defined as present based on eGFR < 60 ml/min per 1.73 m^2, and/or UACR $\geq$30 mg/g.[57] eGFR will be calculated using the recently validated combined creatinine–cystatin C equation, that has been shown to perform better than equations based on either of these markers alone for chronic kidney disease detection.[58,59] Since it has been demonstrated that there is risk gradient within normal range of UACR, we will also evaluate the risk associated with a threshold of 10 mg/g as a sensitivity analysis.[60]

4) ABI (visit 4)

Peripheral arterial disease will be defined as present based on an ABI value < 0.9. Since ABI has been collected at visit 4 in a sample of the total population, for those patients with missing data on this parameter we will carry forward the last available measure from prior visits (visit 1 and 3). For those subjects in whom ABI data is not available at visit 4 or from prior visits, we will assign these participants as negative for PAD. We recognize that this may lead to misclassification bias, but this approach is conservative and would tend to mitigate any association we may find between PAD and incident CVD.

5) Carotid IMT (visit 3 and 4)

CIMT will be defined as the mean of IMT measurements at six sites of the carotid arteries using B-mode ultrasound,[61] with a cut off value for detection of target organ damage of $\geq$1 mm.[62] Since CIMT has been collected in half of the population at visit 4 and the other half at visit 3, for those patients with missing

data on this parameter at visit 4 we will carry forward the last available measure from visit 3.

Serum biomarkers
HsTnT, NTproBNP, hsCRP (visit 4)
Biomarkers will be evaluated as both continuous and categorical variables. For continuous models, undetectable levels of hsTnT will be assigned a value of half the lower limit of detection. For the categorical analysis, NTproBNP will be divided into quartiles, hsCRP values will be dichotomized using the cut point of high risk proposed by the American Heart Association recommendations,[63] while cTnT levels will be separated based on the manufacturer proposed 99th percentile decision limit for the Roche assay.[37,64]

For each serum biomarker, target organ damage will be defined as present if:
   1) *hsTnT ≥ 0.014 $\mu g/L$.*
   2) *NT proBNP in the highest quartile.*
   3) *hsCRP is >3mg/L.* [46]

Outcome variables**:**
Primary outcome
- Composite of fatal and non fatal CV events (defined as CHD, HF and stroke events).[65]
Secondary outcomes
- All cause mortality.
- CV death (CHD, HF, stroke).
- Incident heart failure hospitalization based on diagnosis codes from hospital discharges (ICD-9 code 428.XX). [52]
- Total incident CHD events (fatal CHD, definite or probable MI, or coronary revascularization) ascertained per ARIC study procedures.[66]
- Total incident stroke events (validated stroke death, definite or probable non fatal stroke) ascertained per ARIC study procedures.[67]

Incident CV events will be defined as new events occurring subsequent to the fourth examination through December 31, 2008.

Covariates
Variables of interest will include age, sex, race, center, smoking status, pack of cigarettes/year, body mass index, waist-hip ratio, systolic blood pressure, hypertensive medication use, diabetic medication use, lipid lowering medication, aspirin use, education, triglycerides, total/HDL cholesterol (all detected at visit 4), family history of CHD (per protocol detected only at visit 2).

Statistical Analysis
All non-normally distributed variables will be natural logarithmically transformed, as needed.

First, we will describe characteristics of the diabetic population without prevalent CVD at visit 4 according to the presence of each traditional indicator of target organ damage and of serum biomarkers (continuous variables will be expressed as mean ± SD or median (IQR) and compared with a t-test or Wilcoxon rank-sum test as appropriate, while categorical variables will be presented as counts and percentages and compared using a Fisher exact test).

Second, we will calculate incident event rates, overall and within each category of target organ damage and sub-clinical dysfunction, expressed as events per person-time.

Third we will evaluate risk associated with target organ damage using Cox proportional hazards regression. We will construct four sets of models:
Model 1 will be unadjusted; model 2 will adjust for age, sex, race, center, smoking status, pack of cigarettes/year, body mass index, waist-hip ratio, systolic blood pressure, hypertensive medication use, diabetic medication use, lipid lowering medication, aspirin use, education, total/HDL cholesterol, triglycerides, family history of CHD; model 3a will be further adjusted for traditional indicators of target organ damage and for biomarkers considered as dichotomous variables (considering the following cut off: hsTnT $\geq$ 0.014 μg/L, NT proBNP in the highest quartile, hsCRP >3mg/L); model 3b will feature the same predictors as 3a, but with biomarkers considered as continuous variables.
We will assess the discriminatory ability of each model using a C-statistic. For models 1 and 2, the univariate effect of each key predictor (indicators of target organ damage and biomarkers) will be assessed by considering the addition of only new marker at a time. The associated hazard ratio and resulting C-statistic will be reported for each predictor. Models 3a and 3b will be used to assess the effects of all key predictors, controlling for all others. The hazard ratio for each predictor in these fully adjusted models will be reported.

Fourth we will investigate potential effect modification by novel serum biomarkers on the relationship between each traditional measure of target organ damage and the risk of CV death or nonfatal CHD or HF.

Two-sided *P* values of <0.05 will be considered statistically significant. All analyses will be performed using STATA 12.

Limitations:
The study will be restricted to Caucasians and African Americans; thus the results cannot be generalized to other races. Additionally, the retinal examinations and laboratory analyses of cardiac biomarkers were obtained at different study visits (3 and 4), separated by a period of approximately 3 years. The same holds true for a part of ABI and CIMT data.
We will not be able to rule out the possibility of residual confounding.
The results cannot be generalized to younger population.
CHF events will be defined from hospitalization or death records (both self-reported events and detected by surveillance of community hospital discharges or by surveying

death certificates from state vital statistics). Self-report may result in underreporting of hospitalization, and milder CHF cases that did not require hospitalization won't be included. The latter may limit the applicability of our results to a wider spectrum of CHF cases not requiring inpatient treatment. Additionally, data derived from death certificates may have limited accuracy and it is possible that some CHF events may have been misclassified.

7.a. Will the data be used for non-CVD analysis in this manuscript? ____ Yes _X_ No

   b. If Yes, is the author aware that the file ICTDER03 must be used to exclude persons with a value RES_OTH = "CVD Research" for non-DNA analysis, and for DNA analysis RES_DNA = "CVD Research" would be used? ____ Yes ____ No
(This file ICTDER has been distributed to ARIC PIs, and contains the responses to consent updates related to stored sample use for research.)

8.a. Will the DNA data be used in this manuscript?
    ____ Yes _X_ No

8.b. If yes, is the author aware that either DNA data distributed by the Coordinating Center must be used, or the file ICTDER03 must be used to exclude those with value RES_DNA = "No use/storage DNA"?
    ____ Yes ____ No

9. The lead author of this manuscript proposal has reviewed the list of existing ARIC Study manuscript proposals and has found no overlap between this proposal and previously approved manuscript proposals either published or still in active status. ARIC Investigators have access to the publications lists under the Study Members Area of the web site at: http://www.cscc.unc.edu/ARIC/search.php

   ___X__ Yes   _____ No

10. What are the most related manuscript proposals in ARIC (authors are encouraged to contact lead authors of these proposals for comments on the new proposal or collaboration)?
#546: Subclinical markers and incident CHD in diabetes mellitus; Duncan BS
#606: C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2002 Aug;144(2):233-8. Folsom AR
#781: Subclinical atherosclerosis measures and incident CVD in diabetics; Diabetes Care. 2003 Oct;26(10):2777-84. Folsom AR
#855: Retinopathy and risk of congestive heart failure. JAMA 2005;293:63-9. Wong TY
#1123: Albuminuria and Kidney Function as Predictors of Cardiovascular Events and Mortality; Am J Epidemiol. 2008 May 15;167(10):1226-34. Astor B

#1564: Correlation of high sensitivity troponin-T (hs-cTnT) and amino terminal pro-brain natriuretic peptide (NT-proBNP) with renal function parameters; and association with mortality and adverse cardiovascular events. Circulation 2011;123:1367-76. Saunders J

#1596: Hyperglycemia and risk of subsequent elevation of NT-proBNP and hs-cTnT; J Am Coll Cardiol. 2012 Jan 31;59(5):484-9. Rubin J

#1757: The association of high sensitivity troponin with heart failure, mortality and recurrent coronary heart disease (CHD) in individuals with prevalent CHD. Nambi V

#1759: Associations of traditional cardiovascular risk factors and high-sensitivity cardiac troponin T. Rubin J

#1808: The utility high sensitivity cardiac troponin T in the prediction of heart failure risk. Nambi V

#1811: Association of high sensitive troponin T (hs-cTnT),N- Terminal pro- brain natriuretic peptide (NT-proBNP) and high sensitivity C- reactive protein (hs-CRP) with cause- specific mortality: ARIC study. Oluleye OW

#2031: Interaction of Kidney Disease Measures with Diabetes and Hypertension on Cardiovascular Disease: the Atherosclerosis Risk in Communities (ARIC) Study. Alexander N

11.a. Is this manuscript proposal associated with any ARIC ancillary studies or use any ancillary study data?   **_X_ Yes   ___ No**

11.b. If yes, is the proposal
     _X_   A. primarily the result of an ancillary study (2008.10, 2006.16)
     ___   B. primarily based on ARIC data with ancillary data playing a minor role (usually control variables; list number(s)* _____ _____ _____)

*ancillary studies are listed by number at http://www.cscc.unc.edu/aric/forms/

12a. Manuscript preparation is expected to be completed in one to three years. If a manuscript is not submitted for ARIC review at the end of the 3-years from the date of the approval, the manuscript proposal will expire.

12b. The NIH instituted a Public Access Policy in April, 2008 which ensures that the public has access to the published results of NIH funded research. It is **your responsibility to upload manuscripts to PUBMED Central** whenever the journal does not and be in compliance with this policy. Four files about the public access policy from http://publicaccess.nih.gov/ are posted in http://www.cscc.unc.edu/aric/index.php, under Publications, Policies & Forms. http://publicaccess.nih.gov/submit_process_journals.htm shows you which journals automatically upload articles to Pubmed central.

References

[1] Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet. 2006;368(9529):29-36.

[2] Lotufo PA, Gaziano JM, Chae CU, Ajani UA, Moreno-John G, Buring JE, Manson JE.

[1] Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet. 2006;368(9529):29-36.

[2] Lotufo PA, Gaziano JM, Chae CU, Ajani UA, Moreno-John G, Buring JE, Manson JE. Diabetes and all-cause and coronary heart disease mortality among US male physicians. Arch Intern Med. 2001;161(2): 242-247.

[3] Woodward M, Zhang X, Barzi F, Pan W, Ueshima H, Rodgers A, MacMahon S; Asia Pacific Cohort Studies Collaboration. The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region. Diabetes Care. 2003;26(2):360-366.

[4] Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010 Jun 26;375(9733):2215-22.

[5] Psaty BM, Furberg CD, Kuller LH, Bild DE, Rautaharju PM, Polak JF, Bovill E, Gottdiener JS. Traditional risk factors and subclinical disease measures as predictors of first myocardial infarction in older adults: The Cardiovascular Health Study. Arch Intern Med. 1999;159:1339 –1347.

[6] Manolio TA, Kronmal RA, Burke GL, O'Leary DH, Price TR, for the CHS Collaborative Research Group. Short-term predictors of incident stroke in older adults: the Cardiovascular Health Study. Stroke. 1996;27: 1479–1486.

[7] Hogan P, Dall T, Nikolov P; American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003; 26: 917–932.

[8] Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003; 290: 1884–1890.

[9] Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004; 291: 335–342.

[10] Polonsky KS. The past 200 years in diabetes. N Engl J Med. 2012 Oct 4;367(14):1332-40.

[11] Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies BMJ. 2002; 324: 939–942.

[12] Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, Nathan DM, Manson JE. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med. 2001; 161: 1717–1723.

[13] Miettinen H, Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke. 1996 Nov;27(11):2033-9..

[14] Kuller LH, Arnold AM, Psaty BM, Robbins JA, O'Leary DH, Tracy RP, Burke GL, Manolio TA, Chaves PH. 10-year follow-up of subclinical cardiovascular disease and risk of coronary heart disease in the Cardiovascular Health Study. Arch Intern Med. 2006 Jan 9;166(1):71-8..

[15] Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992; 326: 381–386.

[16] Leng GC, Fowkes FG, Lee AJ, Dunbar J, Housley E, Ruckley CV. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ (Clin Res Ed). 1996; 313: 1440–1444.

[17] Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation. 1985; 71: 510–515.

[18] Ankle Brachial Index Collaboration, Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, Folsom AR, Hirsch AT, Dramaix M, deBacker G, Wautrecht JC, Kornitzer M, Newman AB, Cushman M, Sutton-Tyrrell K, Fowkes FG, Lee AJ, Price JF, d'Agostino RB, Murabito JM, Norman PE, Jamrozik K, Curb JD, Masaki KH, Rodríguez BL, Dekker JM, Bouter LM, Heine RJ, Nijpels G, Stehouwer CD, Ferrucci L, McDermott MM, Stoffers HE, Hooi JD, Knottnerus JA, Ogren M, Hedblad B, Witteman JC, Breteler MM, Hunink MG, Hofman A, Criqui MH, Langer RD, Fronek A, Hiatt WR, Hamman R, Resnick HE, Guralnik J, McDermott MM. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: A meta-analysis. JAMA. 2008;300:197 – 208.

[19] Dineen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997;157:1413–8.

[20] Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15:1307 – 1315.

[21] Karalliedde J, Viberti G: Microalbuminuria and cardiovascular risk. Am J Hypertens 17:986 –993, 2004.

[22] Grimm Jr RH, Svendsen KH, Kasiske B, Keane WF, Wahi MM. Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Kidney Int Suppl 1997;63:S10–4.

[23] Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber MA, Franklin S, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T; ALLHAT Collaborative Research Group. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006;144:172–80.

[24] Hanis CL, Chu HH, Lawson K, Hewett-Emmett D, Barton SA, Schull WJ, Garcia CA. Mortality of Mexican Americans with NIDDM. Retinopathy and other predictors in Starr County, Texas. Diabetes Care 1993;16:82–9.

[25] Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141:334–341.

[26] DeBacquer D, DeBacker G, Kornitzer M, Blackburn H. Prognostic value of ECG findings for total, cardiovascular disease, and coronary heart disease death in men and women. Heart. 1998;80:570 –577.

[27] Bombelli M, Facchetti R, Carugo S, Madotto M, Arenare F, Quarti- Trevano F, Capra A, Giannattasio C, Dell'Oro R, Grassi G, Sega R, Mancia G. Left ventricular hypertrophy increases cardiovascular risk independently. J Hypertens 2009; 27:2458–2464.

[28] Chambless LE, Folsom AR, Clegg LX, Sharrett AR, Shahar E, Nieto FJ, Rosamond WD, Evans G. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2000 Mar 1;151(5):478-87.

[29]Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, Clegg LX. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol. 1997 Sep 15;146(6):483-94.

[30] Galasko GI, Lahiri A, Barnes SC, Collinson P, Senior R. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? Eur Heart J, 2005.26(21):2269-76.

[31] Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA, 2005.293(13):1609-16.

[32] Bibbins-Domingo K, Gupta R, Na B, Wu AH, Schiller NB, Whooley MA. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA, 2007.297(2):169-76.

[33] Magnusson M, Melander O, Israelsson B, Grubb A, Groop L, Jovinge S. Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care, 2004.27(8):1929-35.

[34] Beer S, Golay S, Bardy D, Feihl F, Gaillard RC, Bachmann C, Waeber B, Ruiz J. Increased plasma levels of N-terminal brain natriuretic peptide (NT-proBNP) in type 2 diabetic patients with vascular complications. Diabetes Metab, 2005.31(6):567-73.

[35] Bhalla Chiang A, Epshteyn VA, Kazanegra R, Bhalla V, Clopton P, Krishnaswamy P, Morrison LK, Chiu A, Gardetto N, Mudaliar S, Edelman SV, Henry RR, Maisel AS. Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol, 2004.44(5):1047-52.

[36] Newby LK, Alpert JS, Ohman EM, Thygesen K, Califf RM. Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations. Am. Heart J. 2002;144(6):957–980.

[37] Saunders J, Nambi V, de Lemos J, Chambles LE, Virani SS, Boerwinkle E, Hoogeveen RC, Liu X, Heiss G, Coresh J, Ballantyne CM. Cardiac Troponin T Measured by a Highly Sensitive Assay Predicts Coronary Heart Disease, Heart Failure, and Mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011;123:1367–1376.

[38] Latini R, Masson S, Anand IS, Missov E, Carlson M, Vago T, Angelici L, Barlera S, Parrinello G, Maggioni AP, Tognoni G, Cohn JN. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation. 2007; 116:1242-1249.

[39] Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, Tjora S, Domanski MJ, Gersh BJ, Rouleau JL, Pfeffer MA, Braunwald E. A sensitive cardiac troponin t assay in stable coronary artery disease. N Engl J Med. 2009;361:2538-2547.

[40] de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, Hashim I, Berry JD, Das SR, Morrow DA, McGuire DK. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population.JAMA. 2010 Dec 8;304(22):2503-12.

[41] deFilippi CR, de Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, Seliger SL. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA. 2010 Dec 8;304(22):2494-502.

[42] Everett BM, Cook NR, Magnone MC, Bobadilla M, Kim E, Rifai N, Ridker PM, Pradhan AD. Sensitive cardiac troponin T assay and the risk of incident cardiovascular disease in women with and without diabetes mellitus: the Women's Health Study. Circulation. 2011 Jun 21;123(24):2811-8.

[43] Folsom AR, Aleksic N, Catellier D, Juneja HS, Wu KK. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J.2002;144:233-238.

[44] Ridker PM, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Khurmi NS, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group.Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.Am J Cardiol. 2007 Dec 1;100(11):1659-64.

[45] Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M, Butterworth AS, Amouyel P, Assmann G, Bakker SJ, Barr EL, Barrett-Connor E, Benjamin EJ, Björkelund C, Brenner H, Brunner E, Clarke R, Cooper JA, Cremer P, Cushman M, Dagenais GR, D'Agostino RB Sr, Dankner R, Davey-Smith G, Deeg D, Dekker JM, Engström G, Folsom AR, Fowkes FG, Gallacher J, Gaziano JM, Giampaoli S, Gillum RF, Hofman A, Howard BV, Ingelsson E, Iso H, Jørgensen T, Kiechl S,

Kitamura A, Kiyohara Y, Koenig W, Kromhout D, Kuller LH, Lawlor DA, Meade TW, Nissinen A, Nordestgaard BG, Onat A, Panagiotakos DB, Psaty BM, Rodriguez B, Rosengren A, Salomaa V, Kauhanen J, Salonen JT, Shaffer JA, Shea S, Ford I, Stehouwer CD, Strandberg TE, Tipping RW, Tosetto A, Wassertheil-Smoller S, Wennberg P, Westendorp RG, Whincup PH, Wilhelmsen L, Woodward M, Lowe GD, Wareham NJ, Khaw KT, Sattar N, Packard CJ, Gudnason V, Ridker PM, Pepys MB, Thompson SG, Danesh J. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012 Oct 4;367(14):1310-20.

[46] Soinio M, Marniemi J, Laakso M, Lehto S, Rönnemaa T. High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study. Diabetes Care. 2006 Feb;29(2):329-33.

[47] Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004 Feb 24;109(7):837-42.

[48] Folsom AR, Chambless LE, Duncan BB, Gilbert AC, Pankow JS; Atherosclerosis Risk in Communities Study Investigators. Prediction of coronary heart disease in middle-aged adults with diabetes. Diabetes Care. 2003 Oct;26(10):2777-84.

[49] Ingelsson E, Sullivan LM, Murabito JM, Fox CS, Benjamin EJ, Polak JF, Meigs JB, Keyes MJ, O'Donnell CJ, Wang TJ, D'Agostino RB Sr, Wolf PA, Vasan RS. Prevalence and prognostic impact of subclinical cardiovascular disease in individuals with the metabolic syndrome and diabetes. Diabetes. 2007;56(6):1718-26.

[50] Kuller LH, Velentgas P, Barzilay J, Beauchamp NJ, O'Leary DH, Savage PJ. Diabetes mellitus: subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality. Arterioscler Thromb Vasc Biol. 2000 Mar;20(3):823-9.

[51] Mukamal KJ, Kizer JR, Djoussé L, Ix JH, Zieman S, Siscovick DS, Sibley CT, Tracy RP, Arnold AM. Prediction and classification of cardiovascular disease risk in older adults with diabetes. Diabetologia. 2012 Nov 10. [Epub ahead of print]

[52] Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am. J. Cardiol. 2008;101(7):1016–1022.

[53] Eriksson H, Caidahl K, Larsson B, Ohlson LO, Welin L, Wilhelmsen L, Svärdsudd K. Cardiac and pulmonary causes of dyspnoea—validation of a scoring test for clinical-epidemiological use: the Study of Men Born in 1913. Eur Heart J. 1987;8(9):1007-14.

[54] Klein R, Sharrett AR, Klein BE, Moss SE, Folsom AR, Wong TY, Brancati FL, Hubbard LD, Couper D, ARIC Group: The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the atherosclerosis risk in communities study. Ophthalmology 109:1225– 1234, 2002.

[55] Blackburn H, Keys A, Simonson E, Rataharju P, Punsar S. The electrocardiogram in population studies. A classification system. Circulation. 1960 Jun;21:1160-75.

[56] Furberg CD, Manolio TA, Psaty BM, Bild DE, Borhani NO, Newman A, Tabatznik B, Rautaharju PM. Major electrocardiographic abnormalities in persons aged 65 years and older (the Cardiovascular Health Study). Cardiovascular Health Study Collaborative Research Group. Am J Cardiol. 1992 May 15;69(16):1329-35.

[57] Cirillo M, Lanti MP, Menotti A, Laurenzi M, Mancini M, Zanchetti A, De Santo NG. Definition of kidney dysfunction as a cardiovascular risk factor: Use of urinary albumin excretion and estimated glomerular filtration rate. Arch Intern Med. 2008;168:617 – 624.

[58] Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS; CKD-EPI Investigators. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012 Jul 5;367(1):20-9. Erratum in: N Engl J Med. 2012 Aug 16;367(7):681.

[59] Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005 May 19;352(20):2049-60.

[60] Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010 Jun 12;375(9731):2073-81.

[61] High-resolution B-mode ultrasound reading methods in the Atherosclerosis Risk in Communities (ARIC) cohort. The ARIC Study Group. J Neuroimaging. 1991 Nov;1(4):168-72.

[62] Nguyen-Thanh HT, Benzaquen BS. Screening for subclinical coronary artery disease measuring carotid intima media thickness. Am J Cardiol. 2009 Nov 15;104(10):1383-8.

[63] Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. Circulation. 2003; 107: 499–511.

[64] Saenger AK, Beyrau R, Braun S, Cooray R, Dolci A, Freidank H, Giannitsis E, Gustafson S, Handy B, Katus H, Melanson SE, Panteghini M, Venge P, Zorn M, Jarolim P, Bruton D, Jarausch J, Jaffe AS. Multicenter analytical evaluation of a high-sensitivity troponin T assay. Clin Chim Acta. 2011 Apr 11;412(9-10):748-54.

[65] D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: The Framingham heart study. Circulation. 2008;117:743-753.

[66] White A, Folsom A, Chambless L, Sharret R, Yang K, Conwill D, Higgins M, Dale Williams O, Tyroler HA and the ARIC Investigators. ScienceDirect - Journal of Clinical Epidemiology : Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: Methods and initial two years' experience. Journal of clinical Epidemiology. 1996;49(2):223–233.

[67] Rosamond WD, Folsom AR, Chambless LE, Wang CH, McGovern PG, Howard G, Copper LS, Shahar E. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1999 Apr;30(4):736-43.